Contact this trialFirst, we need to learn more about you.
Kinase Inhibitor
Ripretinib vs Sunitinib for Gastrointestinal Stromal Tumors
Recruiting3 awardsPhase 3
New Haven, Connecticut
This trial is comparing the effectiveness of ripretinib to sunitinib in patients with gastrointestinal stromal tumors (GIST) who did not respond well to their first treatment with imatin
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service